Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31420901 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2CYP2D6ALDH1A1KMT2ALMNA | |
| SCHEMBL31420584 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2CYP2D6ALDH1A1KMT2ALMNA | |
| SCHEMBL31421384 | 0.90 | SMN1; SMN2 (0.69) | SMN1; SMN2CYP2D6ALDH1A1KMT2ALMNA | |
| SCHEMBL31421186 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2CYP2D6ALDH1A1KMT2ALMNA | |
| SCHEMBL31420620 | 0.88 | SMN1; SMN2 (0.69) | SMN1; SMN2CYP2D6ALDH1A1KMT2ALMNA | |
| SCHEMBL31421143 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP2D6ALDH1A1KMT2ALMNA | |
| SCHEMBL31420838 | 0.86 | ALDH1A1 (0.66) | SMN1; SMN2CYP2D6ALDH1A1KMT2ALMNA | |
| SCHEMBL31420826 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP2D6ALDH1A1KMT2ALMNA | |
| SCHEMBL31421136 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2CYP2D6ALDH1A1KMT2ALMNA | |
| SCHEMBL31421532 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2CYP2D6ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | SMN1; SMN2 1576/4885CYP2D6 2401/4885ALDH1A1 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.